Yahoo Finance

Moderna (MRNA) shares tumble after the pharmaceutical company lowered its sales forecast amid weak demand for COVID and RSV vaccines. Seana Smith and Brad Smith outline what investors need to know about the sales cut.

The sales outlook cut comes ahead of President-elect Donald Trump’s return to the White House, fueling uncertainty given that Trump’s Food and Drug Administration (FDA) nomination, Robert F. Kennedy Jr., has been outspoken with his antivaccine views.

To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.

This post was written by Naomi Buchanan.